Previous studies have shown that growth hormone (GH)-deficient children are more responsive to exogenous human growth hormone (HGH) than non-GH-deficient children. In six GH-deficient children, velocity of linear growth was less than 2.5 cm/yr. By the metabolic balance study technique, anabolic responses (increments in elemental balances) were measured to a 7 day course of 0.0532 U HGH/kg body weight (BW)3/4 per day (dose B) and to 0.168 U/kg BW3/4 per day (dose C). They were then treated for 1 yr with HGH at a dose intermediate between B and C. Velocity of linear growth accelerated to 15-25 cm/yr for the first 4-7 mo, then declined to 0-8 cm/yr. At 12 mo, responsiveness to doses B and C was measured again; the responses were only 20-60% as great as before treatment. After 3 mo without HGH treatment, responsiveness to the anabolic effects of doses B and C returned to the magnitudes observed before treatment. A low titer of plasma antibodies to HGH was detected in two of the six children at the end of the year's treatment; these titers showed little change after 3 mo without HGH. Thus the hyperresponsiveness of GH-deficient subjects to exogenous HGH, compared to non-GH-deficient individuals, declines during long-term HGH treatment and is restored by 3 mo interruption of treatment. These changes in peripheral responsiveness may be related to the decline in velocity of linear growth which occurs after 4-7 mo of continuous treatment.
Daniel Rudman, Joseph H. Patterson, Donna L. Gibbas
Title and authors | Publication | Year |
---|---|---|
Consequences of Brand Switches During the Course of Pediatric Growth Hormone Treatment
A Grimberg, C Feudtner, CM Gordon |
Endocrine Practice | 2011 |
Reflecting on 80 years of excellence
U Savla |
Journal of Clinical Investigation | 2004 |
Reflecting on 80 years of excellence
Savla U |
Journal of Clinical Investigation | 2004 |
Endocrine Withdrawal Syndromes
Z Hochberg, K Pacak, GP Chrousos |
Endocrine reviews | 2003 |
Insulin secretion in growth hormone-deficient children and the effect of the sulfonylurea drug glibenclamide on linear growth
E Heinze, W Beischer, WM Teller |
European Journal of Pediatrics | 1978 |
Clinical Neuroendocrinology
CR Edwards |
Clinical Neuroendocrinology | 1977 |
Clinical studies of human growth hormone
AW Root |
Pharmacology & Therapeutics Part C Clinical Pharmacology and Therapeutics | 1976 |
Nitrogen metabolism in growth hormone-deficient children receiving oxandrolone and human growth hormone
MS Zafar, RC Mellinger, C Wolf, LB Morrow, C Whitten, D DeJongh, E Hills |
Metabolism | 1974 |